Efficacy of budesonide in moderate to severe asthma

Clinical Therapeutics

Volumn 24, Issue 6, 2002, Pages 887-905

  O'Connell, Edward J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Asthma; Budesonide; Efficacy, clinical; Pulmicort Respules ; Pulmicort Turbuhaler

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; MOMETASONE FUROATE; PREDNISONE; ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT;

ADULT; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRY POWDER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDLINE; METERED DOSE INHALER; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TITRIMETRY; CLASSIFICATION; HOSPITALIZATION; TREATMENT OUTCOME;

ADULT; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036308259     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80005-4     Document Type: Article

References (64)

1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC
2. Fact sheet
3. British guidelines on asthma management: 1995 Review and position statement
4. Efficacy of inhaled corticosteroids in asthma
5. Effects of longterm treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children
6. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma
7. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma
8. Effect of early vs late intervention with inhaled corticosteroids in asthma
9. Self-reported asthma prevalence among adults - United States 2000
10. Costs of asthma according to the degree of severity
11. Costs of asthma are correlated with severity: A 1-year prospective study
12. Asthma management: Evidence based studies and their implications for cost-efficacy
13. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis
14. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium
15. Do inhaled corticosteroids inhibit growth in children?
16. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma
17. Effect of inhaled formoterol and budesonide on exacerbations of asthma
18. Optimal asthma control, starting with high doses of inhaled budesonide
19. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to longterm treatment
20. Inhaled steroids in moderate asthma: How to use them?
21. Once daily budesonide: Effective control of moderately severe asthma with 800 μg once daily inhaled via Turbohaler when compared with 400 μg twice daily
22. The effect of prescribed daily dose frequency on patient medication compliance
23. Daily regimen and compliance with treatment
24. Fluticasone versus beclomethasone or budesonide for chronic asthma
25. A comparison of the efficacy and safety of inhaled corticosteroids in asthma
26. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification
27. Higher activity of budesonide compared to fluticasone propionate and mometasone furoate after pulse exposure
28. Fatty acid ester formation appears to increase and prolong the retention of budesonide in human nasal mucosa in vivo as compared with fluticasone propionate
29. Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro
30. A 3-month comparative dose-reduction study with inhaled beclomethasone dipropionate and budesonide in the management of moderate to severe adult asthma
31. Clinical efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI with volumatic spacer. A 2-year randomized study in 102 asthma patients
32. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol
33. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 μg/day) versus budesonide dry powder inhaler (800 μg/day) in asthma
34. Efficacy and safety of inhaled corticosteroids. New developments
35. Same minimal effective dose of budesonide Turbuhaler® and fluticasone Diskus®/Accuhaler® in adult asthmatics
36. Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function
37. The effect of high-dose fluticasone propionate and budesonide on lung function and asthma exacerbations in patients with severe asthma
38. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler
39. A role for concentrated formulations of inhaled steroid in severe asthmatics
40. Comparison of alternate-morning prednisone vs. inhaled steroid (IS) for asthma
41. Comparisons between inhaled and oral corticosteroids in patients with chronic asthma
42. High-dose inhaled budesonide in treatment of severe steroid-dependent asthma
43. High dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics. A two-year study
44. Steroid sparing effect of Pulmicort® (budesonide) Turbuhaler® in patients with chronic oral steroid-dependent asthma
45. High-dosage inhalation steroids in asthma - Analysis of costs and use in health care
46. A comparison of oral slow release theophylline and inhaled budesonide in adult asthmatics
47. Effect of long-term treatment with inhaled budesonide or theophylline on airway hyperresponsiveness and clinical asthma
48. Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler in children with mild to moderate asthma
49. Influence of inspiratory flow rate upon the effect of a Turbuhaler
50. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma
51. Budesonide treatment of moderate and severe asthma in children: A dose-response study
52. Once-daily budesonide: 400 μg once daily is as effective as 200 μg twice daily in controlling childhood asthma
53. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler
54. Efficacy and safety of high-dose inhaled steroids in children with asthma: A comparison of fluticasone propionate with budesonide
55. A comparison of the efficacy and safety of a half dose of fluticasone propionate with beclamethasone dipropionate and budesonide in childhood asthma
56. Budesonide inhalation suspension: A review of its use in infants, children and adults with inflammatory respiratory disorders
57. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma
58. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants
59. Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study
60. High dose nebulized steroid in the treatment of chronic steroid-dependent asthma